Daiichi Sankyo
4568.TPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥2.12T | ¥1.89T | ¥1.60T | ¥1.28T | ¥1.04T | ¥962.5bn |
| Operating income | ¥258.0bnr | ¥331.9bn | ¥211.6bn | ¥120.6bn | ¥73.0bn | ¥63.8bn |
| Net income (owners) | ¥279.7bnr | ¥295.8bn | ¥200.7bn | ¥109.2bn | ¥67.0bn | ¥76.0bn |
| Total assets | ¥4.00Tr | ¥3.46T | ¥3.46T | ¥2.51T | ¥2.22T | ¥2.09T |
| Net assets / equity | ¥1.68Tr | ¥1.62T | ¥1.69T | ¥1.45T | ¥1.35T | ¥1.27T |
| Operating cash flow | ¥77.7bn | ¥53.8bn | ¥599.3bn | ¥114.5bn | ¥139.2bn | ¥192.2bn |
| EPS (basic) | ¥151.17r | ¥155.96 | ¥104.69 | ¥56.96 | ¥34.94 | ¥39.17 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 15
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | AnnualAmended | 211 figures · EDINET |
| 2025-04-01 → 2026-03-31 | AnnualAmended | 211 figures · EDINET |
| 2025-04-01 → 2026-03-31 | Annual | 211 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 80 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 213 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 80 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 213 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 106 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 102 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 80 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 211 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 102 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 102 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 80 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 213 figures · EDINET |
22 more reports are still being processed.